Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Milton S. Hershey Medical Center
University of California, San Diego
City of Hope Medical Center
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
St. Jude Children's Research Hospital
Barbara Ann Karmanos Cancer Institute
Northwestern University
University of California, San Diego
Hamad Medical Corporation
Emory University
Massachusetts General Hospital
Bristol-Myers Squibb
University of Massachusetts, Worcester
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Bristol-Myers Squibb
European Society for Blood and Marrow Transplantation
Bristol-Myers Squibb